AXIM
AXIM BIOTECHNOLOGIES INC
Latest price
As of — · Market data by Massive
Market cap
—
Volume
0
Previous close
$0.0033
Day range
$0.0000 – $0.0000
Listed
—
Coverage
10 articles
Price performance
Recent trading
Newsroom
Latest AXIM coverage
AXIM Biotechnologies Partners With Leading Diagnostic Manufacturer Auer Precision to Scale Assay Production
[ad_1] Leading Diagnostic Healthcare Company Signs Contract Manufacturing Agreement in Order to Fulfill Sales of IgE and Lactoferrin DED Diagnostic Assays SAN DIEGO, CA – (NewMediaWire) – December 20, 2023 – AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions
AXIM Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide
[ad_1] Leading Diagnostic Healthcare Company Also Announces Over 50 Initial Clinic Commitments for Its Full Diagnostic Assay Platform SAN DIEGO, CA – (NewMediaWire) – July 12, 2023 – AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, anno
Update: AXIM Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide
[ad_1] Leading Diagnostic Healthcare Company Also Announces Over 50 Initial Clinic Commitments for Its Full Diagnostic Assay Platform SAN DIEGO, CA – (NewMediaWire) – July 12, 2023 – AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, anno
AXIM Biotechnologies Announces Over 40 Initial Clinic Commitments for Its Full Diagnostic Assay Platform Launch
[ad_1] Leading Dry Eye Disease Diagnostic Healthcare Company’s Assays to be Performed in Over 40 Initial Clinics Across US SAN DIEGO, CA – (NewMediaWire) – May 24, 2023 – AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today
AXIM Biotechnologies CEO Issues Letter to Shareholders
[ad_1] Summary: • In 2022, AXIM® finalized optimization of its R&D and manufacturing infrastructure to be used in its diagnostic program • AXIM will continue to generate revenue from its two FDA-cleared dry eye disease (DED) diagnostic tests through commercialization partner Verséa Ophthalmics • AXIM anticipates its business to be cash-flow
Medical Marijuana, Inc. Reports $7.8 Million in Net Revenue in 2022 First Quarter Financial and Operational Results
[ad_1] San Diego, CA – (NewMediaWire) – May 19, 2022 – Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today its financial results for the quarter ending
Medical Marijuana, Inc. Subsidiary Kannaway Celebrates Best Revenue Month in Company History for South Africa Division in March 2022
[ad_1] Africa’s cannabis industry is rapidly expanding, becoming one of the Company’s top international growth markets, and is projected to be a $7 billion market by 2023. Reach and Markets highlights that the South African cannabis/cannabidiol (CBD) market is expected to see a CAGR of 28.4% Between 2022 and 2026. “2022 has been a truly ...
Medical Marijuana, Inc. Provides Update on its Pharmaceutical Initiatives
[ad_1] SAN DIEGO, CA – (NewMediaWire) – April 07, 2022 – Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply chain, is pleased to provide a corporate update on its pharmaceut
Medical Marijuana, Inc. Reports $34.1 Million in Revenue in 2021 Annual Financial and Operational Results Filing
[ad_1] SAN DIEGO, CA – (NewMediaWire) – April 01, 2022 – Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply chain, today announced its financial results for the year ending D
Medical Marijuana, Inc. Investment Company AXIM Biotechnologies Files Patent for Worlds First Face Mask Designed to Capture SARS-CoV-2 (COVID-19)
[ad_1] San Diego, CA – (NewMediaWire) – October 06, 2020 – Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its investment company AXIM® Biotechn